
Catheter Directed Thrombolysis May Lower Mortality In Acute PE, But At Expense Of Higher Bleeding: JACC Study
- byDoctor News Daily Team
- 18 February, 2025
- 0 Comments
- 0 Mins

The optimal treatment strategy of intermediate risk patients with pulmonary embolism (PE) remains controversial. Whether to continue with sole anticoagulation (AC) strategy as done with low risk patients or to switch to systemic thrombolysis (ST) as indicated for high risk patients is guided by factors like myocardial strain and hypotension. However the role of more safer catheter directed therapy (CDT) is still not well defined by guidelines.
In this week’s issue of JACC: Cardiovascular Interventions, Zhang et al have published a network meta-analysis to compare the outcomes of anticoagulation (AC) alone, CDT, and ST in the treatment of acute PE. The authors found that compared to AC alone, CDT was associated with a lower risk of mortality, whereas ST was associated with a higher risk of mortality compared to CDT. Notably, this held true even when restricted to the subgroup of patients with intermediate-risk PE.
The analysis included 45 studies that comprised >80,000 patients, including 17 RCTs, 2 prospective nonrandomized studies, and 26 retrospective observational studies. Efficacy outcome was all-cause mortality. Safety outcomes were major bleeding and intracranial hemorrhage (ICH).
The salient findings of the study were:
1. When compared with AC alone, CDT had lower mortality higher major bleeding and numerically higher ICH.
2. ST was associated with no difference in mortality but higher major bleeding (and ICH) compared with AC alone.
3. The risk of mortality and ICH was higher with ST when compared with CDT.
Findings were similar when analysis was restricted to trials of intermediate risk PE.
In conclusion, the data affirm that the best treatment (lowest event rate) for efficacy (all-cause mortality) was CDT, but for safety (major bleeding) the better treatment option was AC alone.
CDT : Still an evolving strategy..
“A notable absence in the analysis is the exclusion of and discussion of aspiration thrombectomy devices, which are gaining momentum in clinical practice with their potentially lower risk of bleeding compared with CDT. Innovations in catheter-based treatments, namely thrombectomy devices, appear to be outpacing societal guidelines”, noted Tefera et al in an accompanying editorial highlighting broader and much safer future applications for CDT.
Ongoing studies are evaluating catheter-based thrombectomy as a thrombolytic-free option for the management of large volume PE. This approach may offer a safe and effective alternative to thrombolytic therapy, especially in patients who are at high risk of bleeding or have contraindications to thrombolytic therapy.
Source: JACC CI:
1. DOI: 10.1016/j.jcin.2023.07.042
2. DOI: 10.1016/j.jcin.2023.08.029
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.

Recent News
Normal-Tension Glaucoma Closely Associated With Co...
- 10 October, 2022
Air Pollution Tied To Increased Risk Of Premature...
- 24 May, 2023

Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!